Literature DB >> 16871891

Decompression of cavernous sinus meningioma for preservation and improvement of cranial nerve function. Technical note.

William T Couldwell1, Peter Kan, James K Liu, Ronald I Apfelbaum.   

Abstract

Meningiomas are the most common tumors affecting the cavernous sinus (CS). Despite advances in microsurgery and radiosurgery, treatment of CS meningiomas remains difficult and controversial. As in cases of other meningiomas, the goal of treatment for CS meningioma is long-term growth control and preservation of neural function. Gross-total resection, the ideal treatment for meningioma, is not always possible to obtain in patients with CS meningiomas with an acceptable level of morbidity. Therefore, microsurgery and radiosurgery have recently been advocated as a combined therapy to achieve good control of tumor growth and favorable functional outcome. The authors describe a technique in which tumor volume can be reduced to a minimal residual amount, while preserving cranial nerve function. This enables the smallest field to be treated radiosurgically. The optic nerve is decompressed, and the tumor mass is reduced to provide at least a 5-mm interpositional distance between the optic nerve and the residual lesion. Direct decompression of the CS, with opening of the lateral and superior sinus walls, and piecemeal removal of the tumor in "safe" locations are performed to facilitate an improvement in cranial nerve function. The authors describe the use of this technique in a series of patients and demonstrate improvement of cranial nerve function in a subset of these patients.

Entities:  

Mesh:

Year:  2006        PMID: 16871891     DOI: 10.3171/jns.2006.105.1.148

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 3.  Aborting a neurosurgical procedure: analyzing the decision factors, with endoscopic third ventriculostomy as a model.

Authors:  Jonathan Roth; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-03-06       Impact factor: 1.475

4.  Cavernous Sinus Meningioma with Orbital Involvement: Algorithmic Decision-Making and Treatment Strategy.

Authors:  Amol Raheja; William T Couldwell
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-17

5.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

6.  Use of sodium fluorescein in skull base tumors.

Authors:  Carlos Eduardo da Silva; Jefferson Luis Braga da Silva; Vinicius Duval da Silva
Journal:  Surg Neurol Int       Date:  2010-10-30

Review 7.  Management options for cavernous sinus meningiomas.

Authors:  Michael T Walsh; William T Couldwell
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

8.  A prospective study of cavernous sinus surgery for meningiomas and resultant common ophthalmic complications (an American Ophthalmological Society thesis).

Authors:  Steven Newman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  Role of stereotactic radiosurgery in meningiomas and vestibular schwannomas.

Authors:  Jeffrey T Jacob; Michael J Link; Bruce E Pollock
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

Review 10.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.